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Diffuse large B-cell lymphoma of Waldeyer’s ring has
distinct clinicopathologic features: a GELA study
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Background: Diffuse large B-cell lymphomas (DLBCLs) arising in speciﬁc extranodal sites have peculiar
clinicopathologic features.
Patients and methods: We analyzed a cohort of 187 primary Waldeyer’s ring (WR) DLBCLs retrieved from GELA
protocols using anthracyclin-based polychemotherapy.
Results: Most patients (92%) had stage I–II disease. A germinal center B-cell-like (GCB) immunophenotype was
observed in 61%, and BCL2 expression in 55%, of WR DLBCLs. BCL2, BCL6, IRF4 and MYC breakpoints were
observed in, respectively, 3 of 42 (7%), 9 of 36 (25%), 2 of 26 (8%) and 4 of 40 (10%) contributive cases. A variable
follicular pattern was evidenced in 30 of 68 (44%) large biopsy specimens. The 5-year progression-free survival (PFS)
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and the overall survival (OS) of 153 WR DLBCL patients with survival information were 69.5% and 77.8%, respectively.
The GCB immunophenotype correlated with a better OS (P = 0.0015), while BCL2 expression predicted a worse OS
(P = 0.037), an effect overcome by the GCB/non-GCB classiﬁcation. Compared with matched nodal DLBCLs, WR
DLBCLs with no age-adjusted international prognostic index factor disclosed a better 5-year PFS rate (77.5% versus
70.7%; P = 0.03).
Conclusions: WR DLBCLs display distinct clinicopathologic features compared with conventional DLBCLs, with usual
localized-stage disease, common follicular features and a high frequency of GCB immunophenotype contrasting with a
low rate of BCL2 rearrangements. In addition, they seem to be associated with a better outcome than their nodal
counterpart.
Key words: clinicopathologic features, diffuse large B-cell lymphomas, outcome, Waldeyer’s ring
introduction
About one-third of diffuse large B-cell lymphomas (DLBCLs)
manifest primarily in non-nodal locations [1]. In the recent
WHO classiﬁcation, subsets of DLBCLs arising in peculiar
extranodal sites have been individualized as distinct disease
subgroups (primary DLBCLs of the central nervous system,
primary cutaneous DLBCLs, leg-type) or as distinct disease
entities (primary mediastinal large B-cell lymphoma), based
on speciﬁc clinical and/or pathologic features [2–4]. Yet, the
majority of extranodal DLBCLs remain categorized as DLBCLs,
not otherwise speciﬁed (NOS).
Waldeyer’s ring (WR) represents one of the most common
extranodal sites for DLBCL development [5], comprising up to
20% of the cases [6]. Peculiar features have been suggested for
WR DLBCLs. Clinically, a relationship to gastrointestinal tract
involvement has been mentioned, either concurrent with
diagnosis or at subsequent relapse [7–9]. Pathologically, the
presence of focal follicular features has been reported in a
subset of tonsillar DLBCLs, suggesting a morphologic
subgroup distinct from de novo nodal DLBCLs, possibly
corresponding to either transformed follicular lymphomas, or
transformed marginal zone lymphomas with follicular
colonization [10]. Genetically, translocations affecting the IRF4
locus in 6p25 have recently observed in a subtype of germinal
center-derived B-cell lymphomas frequently manifesting in the
cervical region including the WR and particularly affecting
children and young adults [11]. Several clinical comparative
studies of nodal versus WR DLBCLs have variably suggested
differences in response to therapy and outcome, or similar
features [9, 12–14]. However, published series are based on
rather limited cohorts of patients, oftentimes heterogeneous
with respect to histopathology, and rarely correlated clinical
and pathologic features [9, 14–20].
The purpose of this work was to study the pathologic
features of primary WR DLBCLs, and to compare their clinical
outcome with that of nodal DLBCLs, based on the analysis of a
retrospective series of well-characterized patients with a long




The GELA ﬁles were searched for patients diagnosed with primary
DLBCLs of the WR (coded as palatine tonsil, lingual tonsil or
nasopharynx). Of 208 with pathologic documentation of a WR DLBCL
consecutively enrolled into the protocols LNH93, LNH98, LNH01 and
LNH03 between 1993 and 2003, 187 qualiﬁed for primary WR DLBCLs.
Outcome analysis and clinicopathologic correlations were restricted to a
subset of 153 patients with available updated survival information,
corresponding to the protocols LNH 93-1 to 93-5, LNH 98-2 and LNH
98-5 (summarized in supplementary Table S1, available at Annals of
Oncology online) [6, 21–25]. All patients had received anthracyclin-based
polychemotherapy without immunotherapy, except for two patients treated
with R-CHOP in the LNH 98.5 trial.
matching with nodal DLBCL patients
For the comparison of outcome, WR DLBCL patients with clinical
annotations were matched to DLBCL patients presenting with nodal
involvement, on the basis of sex, age (<60 versus >60 years), age-adjusted
international prognostic index (aaIPI) and randomization arm, leading to
135 pairs. Comparison of outcome was further restricted to a subset of
107 pairs of patients with no aaIPI factor.
pathologic studies
The archival slides that had been centrally reviewed at the time of
enrollment into clinical trials, comprising 74 surgical specimens (large
biopsies or excisions) (40%) and 113 sampling biopsies (60%), were re-
examined by 2 hematopathologists (LdeL and PG) for cytologic
characterization, according to the variants described in the WHO
classiﬁcation [2], and for the assessment of the pattern of growth. All cases
by deﬁnition exhibited at least partially a diffuse pattern, and were
categorized as: purely diffuse (D), predominantly diffuse (D > N) or
predominantly nodular (N≥D). A tissue microarray (TMA) comprising
two 0.6 mm cores representative of 59 cases with available tissue blocks
was constructed in duplicate.
immunohistochemistry
Immunohistochemistry was carried out using an indirect
immunoperoxidase method. The following markers were used after
appropriate antigen retrieval: BCL2, CD20, CD44, CNA.42, HLADR,
MUM-1/IRF4 (DakoCytomation, Glostrup, Denmark); BCL6 (Ventana,
Tucson, AZ); CD5, CD10, CD21, CD23, cyclin D1 (Novocastra, Newcastle,
UK). The presence of Epstein-Barr virus (EBV) was detected by in situ
hybridization with probes speciﬁc for EBV-encoded small RNA (EBER)
sequences (DakoCytomation). Slides were evaluated semi-quantitatively by
two independent observers (LdeL and PG). A positivity threshold was
deﬁned at 50% for BCL2 [26], and at 30% for BCL6, CD10 and MUM-1
[27]. CD21, CD23 and/or CNA.42 were used for the staining of follicular
dendritic cell (FDC) meshworks. In case of negativity, only the cases with
internal positive controls were recorded. Classiﬁcation into germinal center
B-cell-like (GCB) versus non-GCB immunophenotypes was based on the
algorithm of Hans et al. [27].
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A subset of cases were studied by interphase FISH on TMA sections, using
split-signal DNA probes targeting MYC/8q24, BCL2/18q21 and BCL6/
3q27genes (probes Y5410, Y5407, Y5408; Dako, SA, Glostrup, Denmark)
according to the manufacturer’s recommendations (www.euro-ﬁsh.org) and
analyzed and scored as recently reported [28]. For the detection of
breakpoints affecting the IRF4 locus, two different break-apart assays using
differently labeled BAC/PAC clones were carried out [11].
statistical analyses
Results were expressed as means ± standard deviations, medians and ranges
for continuous variables and as proportions for categorical variables.
Associations between pathologic variables were tested using the chi-square
test. End points of interest were complete response (CR), progression-free
survival (PFS) (deﬁned as the time interval between randomization to
primary treatment failure, relapse and death from any cause or last follow-
up) and overall survival (OS) (deﬁned as the time interval between
randomization to last follow-up or death from any cause). The OS and PFS
were analyzed using a Cox regression model taking matching into account.
The OS and PFS were displayed by Kaplan–Meier curves in each group.
Within the WR DLBCL group, the OS and PFS were evaluated using
univariate and multivariate Cox regression models. Results were considered
signiﬁcant at the 5% level (P < 0.05). Statistical analyses were carried out
using the SAS (version 9.1 for Windows) statistical package.
results
clinical presentation of WR DLBCL patients
The 187 patients with primary WR DLBCLs comprised 169
patients with stage I–II disease, and 18 stage IV patients due to
extensive local disease (n = 7) or dissemination limited to the
bone marrow (n = 11). The population of patients with clinical
follow-up comprised 106 men and 47 women at a median age
of 57 years. Of these 153 patients, 141 had stage I or II disease
and 12 patients (8%) had stage IV disease, due to locally
invasive disease (n = 5) or bone marrow involvement (n = 7).
The aaIPI, available for 144 patients, was 0 in 114 patients
(79%), 1 in 27 patients (19%) and 2 in 3 patients (2%).
WR DLBCLs disclose a predominantly
centroblastic morphology and a high prevalence of
GCB-like immunophenotype
Of the 187 cases, 175 were classiﬁed as centroblastic (CB), 7 as
immunoblastic (IB) and 5 were unclassiﬁable (Table 1). The
prevalence of differentiation antigen expression was the
following: CD10, 68 of 158 (43%), BCL6, 35 of 69 (51%),
MUM-1, 36 of 99 (36%). The global immunophenotypic
proﬁle was GCB in 74 of 122 cases (61%) and non-GCB in
39%. The GCB immunophenotype was associated with CB
morphology (P = 0.012). BCL2 expression in 93 of 168 cases
(55%) correlated with a non-GCB immunophenotype
(P < 0.0001). CD5 positivity was observed in 9 of 60 cases
(15%) (all negative for cyclin D1). Positivity for CD44 (in 8 of
59 cases, 14%) correlated with a non-GCB immunophenotype
(P = 0.003). Loss of HLA-DR expression was detected in 6 of
55 cases (11%) and correlated with BCL2 positivity (P = 0.04).
EBER in situ hybridization was positive in lymphoma cells in
2 of 59 cases.
infrequent BCL2 breaks in WR DLBCLs
Evaluable FISH results of at least two loci were obtained for 42
cases sampled in the TMA (Table 2). Only three cases of 42
(7%) harbored a BCL2 rearrangement, one as the sole
chromosomal break, and one each in association with BCL6 or
MYC rearrangement. All three were positive for BCL2 by
immunohistochemistry, two had a GCB immunophenotype
and one was non-GCB. Nine cases of 36 assessable (25%) (5
GCB and 4 non-GCB) harbored a BCL6 rearrangement, of
which 3 were positive for BCL6 expression. An MYC
Table 1. Morphologic and immunophenotypical features of primary WR DLBCLs
All WR DLBCL
patients (n = 187)
WR DLBCL patients
with clinical
follow-up (n = 153)a
Correlation with outcome
Morphology
Centroblastic 175/187 (93%) 142/153 (93%) NS
Immunoblastic 7/187 (4%) 6/153 (4%) NS
Unclassiﬁable 5/187 (3%) 5/153 (3%) NS
Immunophenotype
CD10 positivity 68/158 (43%) 58/131 (44%) Correlates with a better PFS (P = 0.0055) and OS (P = 0.014)
BCL6 positivity 35/69 (51%) 26/50 (52%) Correlates with a better OS (P = 0.048)
MUM-1 positivity 36/99 (36%) 30/78 (38%) Adversely affects the PFS (P = 0.0046)
GCB immunophenotype 74/122 (61%) 62/100 (62%) Correlates with a better PFS (P = 0.0003) and OS (P = 0.001)
BCL2 positivity 93/168 (55%) 76/136 (56%) Adversely affects the PFS (P = 0.017) and OS (P = 0.037)
CD5 positivityb 9/60 (15%) 7/44 (16%) NS
CD44 positivityb 8/59 (14%) 7/43 (16%) NS
HLA-DR positivityb 49/55 (89%) 35/40 (88%) Correlates with a better PFS (P = 0.04) and OS (P = 0.017)
GCB, germinal center B-cell-like immunophenotype; OS, overall survival; PFS, progression-free survival; WR DLBCL, Waldeyer’s ring diffuse large B-cell
lymphoma; NS, non-signiﬁcant.
aThe results obtained for this subset of the population did not differ signiﬁcantly from those obtained for the 187 patients.
bCarried out on TMAs.
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rearrangement was detected in 4 of 40 assessable cases (10%)
(one GCB and 3 non-GCB), as the sole chromosomal break in
one case, in addition to a BCL6 rearrangement in two cases,
and in conjunction with a BCL2 break in one case. None had
immunomorphologic features of Burkitt lymphoma. A
breakpoint affecting the IRF4 locus was observed in 2 of 26
(8%) assessable cases. Both cases had a partly nodular
architecture and both cases had a GCB immunophenotype
(CD10+); one case occurred in a 79-year-old woman who was
treated without anthracyclin-containing polychemotherapy.
The other one occurred in a 32-year-old man who was treated
by CHOP (cyclophosphamide, adriamycin, vincristine and
prednisone) followed by IFRT (involved-ﬁeld radiotherapy).
The two patients achieved a complete remission.
WR DLBCLs frequently exhibit a partially nodular
growth pattern
Although all cases fulﬁlled the DLBCL diagnostic criteria and
the majority of the cases (144 cases, 77%) exhibited a purely
diffuse distribution of the neoplastic cells, a subset of cases
(43 cases, 23%) had some nodular features. This observation
was substantiated by immunohistochemistry carried out on
surgical specimens, which demonstrated FDC meshworks in
31 of 69 (45%) assessable cases including 7 of 34 (20%) of
those purely diffuse by morphology. The staining corresponded
to either ill-deﬁned FDC meshworks, suggestive of follicular
colonization (n = 15), or to sharply delineated neoplastic
follicles, suggestive of a truly follicular pattern (n = 16)
(Figure 1). Among these cases comprising FDC meshworks,
14 of 25 assessable cases had a GCB immunophenotype and
11 were non-GC; at the genetic level, 8 had a normal
hybridization pattern with the split probes tested and 6 had an
abnormal pattern (2 cases with a BCL6 break, 1 case with an
MYC break, 1 case with an IRF4 break, 2 cases with double
rearrangements involving BCL2 and either MYC or BCL6).
the overall good outcome of WR DLBCL patients
correlates with the GCB-like immunophenotype
Response to therapy was known for 146 of 153 patients and
CR was achieved in 135 of 146 of them (92%). Thirty
Table 2. FISH results in primary WR DLBCLs
BCL2 break BCL6 break MYC break IRF4 break
All cases 42 3/42 (7%) 9/36 (25%) 4/40 (10%) 2/26 (8%)
GCB 25 2/26 5/22 1/24 2/16
Non-GCB 17 1/16 4/14 3/16 0/10
GCB, germinal center B-cell-like immunophenotype; WR DLBCL,
Waldeyer’s ring diffuse large B-cell lymphoma.
Figure 1 Follicular features in Waldeyer’s ring diffuse large B-cell lymphomas (WR DLBCLs). (A–C) WR DLBCL displaying a partially follicular growth
pattern (A: hematoxylin and eosin, ×100, B: CD21, immunoperoxidase, ×100; C: CD20, immunoperoxidase, ×100). (D–F): WR DLBCLs with large ill-
deﬁned follicular structures consistent with follicular colonization (D: hematoxylin and eosin, ×50; E: CD21, immunoperoxidase, ×100; F: BCL2,
immunoperoxidase, ×200).
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Figure 2 Progression-free (A) and overall survival (B) of Waldeyer’s ring diffuse large B-cell lymphoma patients according to the germinal center B-cell-like
(GCB)/non-GCB immunophenotype.
Figure 3 Comparison of the outcome of diffuse large B-cell lymphoma patients presenting with Waldeyer’s ring (WR) versus nodal involvement. Panels A
and C feature the 5-year progression-free survival, and panels B and D the 5-year overall survival of 135 pairs of matched WR and nodal patients (A and B)
and of 107 pairs of matched patients with no age-adjusted international prognostic index factor (C and D).
Annals of Oncology original articles
Volume 23 | No. 12 | December 2012 doi:10.1093/annonc/mds150 | 







patients relapsed, at the initial site of presentation in 46%
and in a novel site in 54%. Only one relapse occurred in
the digestive tract. With a median follow-up of 66 months,
the 5-year OS for the 153 patients was 77.8% (95% CI:
70.5% to 85.9%) and the 5-year PFS was 69.5% (95% CI:
61.6% to 78.4%).
The clinical features at the time of diagnosis were tested for
their impact on outcome and response to treatment (Table 3).
Age >60 years and higher aaIPI correlated with a shorter PFS
and OS. The CR rate and the 5-year PFS were both adversely
affected by a higher disease stage and a higher aaIPI.
Regarding associations with pathologic features (Table 1),
no correlation was found with cytologic features, nor with a
growth pattern. Expression of CD10 and a GCB-like
immunophenotype strongly correlated with a better PFS
(P = 0.0055 and P = 0.0003, respectively) and OS (P = 0.014
and P = 0.001, respectively) (Figure 2). MUM-1 expression
adversely affected PFS (P = 0.0046), and BCL6 expression
was associated with a better OS (P = 0.048). BCL2 expression
was predictive of shorter PFS (P = 0.017). These correlations
remained signiﬁcant irrespective of the aaIPI. However,
BCL2 expression did not retain its adverse effect in a
bivariate model, considering the GCB versus non-GCB
proﬁle together with BCL2 expression, while the
good prognostic value of the GCB immunophenotype
remained signiﬁcant for both the PFS (P = 0.014) and the
OS (P = 0. 047).
a better outcome for WR DLBCL patients
compared with matched nodal DLBCL patients
The outcome of 135 matched pairs of DLBCL patients with
either primary WR or nodal presentation was compared. CR
was achieved in 123 of 134 (92%) versus 112 of 132 (85%) for
WR versus nodal DLBCL patients (P = 0.078). With a median
follow-up of 59 months, the 5-year PFS and OS estimates were
69% (95% CI: 61.6% to 78.4%) and 78% (95% CI: 71.4% to
85.7%) for WR lymphomas versus 67% (95% CI: 59.3% to
75.6%) and 78% (95% CI: 70.5% to 85.9%) for nodal
lymphomas (P = 0.22 and 0.39 for the PFS and OS,
respectively) (Figure 3A and B).
The same analysis was subsequently applied to the 107 pairs
of patients with no aaIPI factor (from the LNH 93-1 and LNH
93-4 protocols; see supplementary Table S1, available at Annals
of Oncology online) (Figure 3C and D). In this subgroup, the
CR rate was 100% for WR DLBCL patients and 87% for nodal
DLBCL patients (P = 0.0001). With a median follow-up of 79
months, the 5-year PFS was 77% (95% CI: 70.4% to 87.5%) for
WR and 71% (95% CI: 62.9% to 80.5%) for nodal DLBCL
patients (P = 0.027). WR DLBCL patients also tended to have a
better OS, with 5-year estimates of 84% (95% CI: 77.5% to
92.5%) versus 80% (95% CI: 72.5% to 88.0%) for nodal
lymphomas (P = 0.07).
discussion
In this report, we have investigated the clinical and pathologic
characteristics of primary WR DLBCLs, with the aim of
delineating the intrinsic features of DLBCLs in this anatomic
site. Our study based on a cohort of 187 patients with primary
WR DLBCLs, including 153 cases with updated survival
information, represents the largest series of primary WR
DLBCLs reported so far [9, 20, 29].
Our analysis has shed light on peculiar pathologic features of
WR DLBCLs, somewhat different from those usually reported
for DLBCLs, NOS. First, we show that WR DLBCLs comprise a
majority of tumors (60%) with a GCB-like phenotypic proﬁle.
Most unselected series of nodal and extranodal DLBCLs
categorized according to the Hans algorithm report a
substantially higher proportion of lymphomas with a non-
GCB-like immunophenotype [27, 28, 30–32]. In a way similar
to us, although their series was rather small, Lopez-Guillermo
et al. [13] also found a higher prevalence of tumors with a GCB
phenotype among WR DLBCLs than in nodal cases [9 of 12
cases (75%) versus 36 of 77 cases (47%)]. Second, the frequency
and distribution of genetic alterations explored by FISH differ
from those reported in unselected series in respect of a low
frequency of BCL2 rearrangements (7%). This ﬁnding is
particularly paradoxical since this alteration, reported in
20%–30% of DLBCLs, is strongly associated with a GCB
immunophenotype [28, 33]. Conversely, the frequency of BCL6
and MYC rearrangements in 25% and 10% of cases,
respectively, is similar to those usually reported [34]. Finally,
DLBCLs of the WR frequently exhibit, to variable extent, a
follicular growth pattern, a feature better seen in surgical
specimens. The presence of follicular features in tonsillar
DLBCLs has been reported by Ree et al. [10], although at a
Table 3. Clinical characteristics and outcome of 153 patients with primary
WR DLBCLs
Clinical features Correlation with outcome
Sex
Male 106/153 (69%) NS
Female 47/153 (31%)
Age (years)
>60 64/153 (42%) Older age adversely
affects the PFS (P = 0.0028)
and OS (P = 0.0006)
<60 89/153 (56%)
median (range) 57 (20–85)
Ann Arbor stage
Stage I–II 141/153 (92%) Advanced-stage adversely
affects CR (P = 0.013)
and PFS (P = 0.0036)
Stage IV 12/153 (8%)
LDH levelsa
Normal 123/144 (85%) NS
Increased 21/144 (15%)
Performance status (PS)a
PS 0–1 143/144 (99%) NA
PS>1 1/144 (1%)
aaIPIa
aa IPI 0 114/144 (75%) Higher aaIPI adversely
affects CR (P = 0.0021),
OS (P = 0.035)
and PFS (P = 0.011)
aa IPI 1 27/144 (22%)
aa IPI 2–3 3/144 (3%)
BM involvement 7/144 (5%) NS
OS, overall survival; PFS, progression-free survival; WR DLBCL, Waldeyer’s
ring diffuse large B-cell lymphoma; aaIPI, age-adjusted International
Prognostic Index; NS, non-signiﬁcant; NA, not applicable.
aAvailable for 144 patients.
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lower frequency. The signiﬁcance of the follicular pattern,
however, remains unclear. In about half of the cases, a minor
nodular pattern with poorly delineated follicles was suggestive
of follicular colonization by DLBCLs in a site naturally
containing many hyperplastic follicles. In such cases, the
possibility of transformed marginal zone lymphoma with
follicular colonization was considered but could not be
conﬁrmed given the absence of a small cell component of these
tumors, and the absence of a true marginal zone pattern. In the
other half of cases, the presence of sharply delineated neoplastic
follicles was rather suggestive of a truly follicular pattern.
However, these cases appear to be heterogeneous at the genetic
level with only a minority (two of eight cases with contributive
FISH analysis) harboring a BCL2 rearrangement of
conventional follicular lymphoma, while conversely a subset
harbor a BCL6 break (two of eight cases), or an IRF4
rearrangement (one of eight cases). Interestingly, BCL6
rearrangements typically uncommon in grades 1–3A follicular
lymphoma (FL) are detected in up to one-third of grade 3B
cases, especially those associated with DLBCLs [35–38], and
translocations activating IRF4 identify a subtype of germinal
center-derived B-cell lymphoma affecting predominantly
children and young adults [11]. Thus, at least a small
proportion of WR DLBCLs likely arise in association with
grade 3B FLs harboring a BCL6 or IRF4 rearrangement. It is
also noteworthy that the palatine tonsils and nasopharynx are
among the most common sites of pediatric FL [39]. These, in
contrast to the common adult type of FL, usually lack BCL2
gene rearrangements, are grade 3B, usually present with
localized disease and have an excellent prognosis. Thus, the
possibility that a subset of transformed FL in the WR may be
related to transformed FL is questionable.
DLBCLs of the WR represent a group of extranodal
DLBCLs associated with a favorable outcome with an
estimated 5-year OS of 80% and a PFS of 72% in this
retrospective cohort of 153 subjects treated with
polychemotherapy alone before rituximab era (except for two
patients). Among the clinical and pathologic factors tested for
their association with survival, age >60 years, the non-GCB
immunophenotype and positivity for BCL2 were identiﬁed as
adverse prognostic factors.
Strikingly, the GC and non-GC immunophenotypic proﬁle
intended to reﬂect the cell-of-origin classiﬁcation had a highly
signiﬁcant impact on both the PFS and the OS. Independent
studies have established that, when deﬁned by gene expression
patterns, the cell-of-origin classiﬁcation into GC and non-GC
subgroups is a strong predictor of survival in patients treated by
chemotherapy, as well as immunochemotherapy [40–46].
Conversely, the predictive value of cell-of-origin
phenotyping on parafﬁn-embedded tissues by the combined
immunostaining of CD10, BCL6 and MUM-1, using Hans
algorithm [27], is more controversial [28, 30–32, 47–49]. Our
study shows the strong prognostic value of the GC/non-GC
classiﬁcation in a retrospective multicentric series composed
exclusively of extranodal DLBCLs in a single anatomic region
(Figure 2). Although the actual correspondence of the phenotypic
and transcriptomic categorizations cannot be assessed, the
observed correlation between the GC phenotype and a CB
morphology, on the one hand, and between a non-GC phenotype
and CD44 and BCL2 expression, on the other hand, lends
support to the reliability of the immunophenotypic classiﬁcation.
Reports in the literature on BCL2 expression as a prognostic
biomarker have been contradictory; although multiple large-
scale trials have established an association between BCL2
expression and a decreased PFS or OS in DLBCLs [26, 30, 50,
51], recent studies have suggested that the prognostic value of
BCL2 expression is overcome by the use of rituximab [52] and
may be restricted to non-GCB tumors only [53]. In this
clinically homogeneous cohort of patients treated before the
era of rituximab, we conﬁrm the results previously reported by
our group on the prognostic value of BCL2expression on both
the PFS and the OS, irrespective of the aaIPI [26]. However, in
bivariate analysis, the adverse effect of BCL2 expression was
overcome by the GCB/non-GCB immunophenotype.
In our study, WR DLBCLs appear to carry a better outcome
compared with matched nodal DLBCLs, a difference that
reached signiﬁcance for the PFS of patients with localized
disease and no adverse factor of the aaIPI in this retrospective
series of patients treated with chemotherapy. Whether
immunochemotherapy protocols would alleviate this difference
and/or could still improve the outcome of patients with
primary WR remains to be investigated. Nevertheless, the
clinical characteristics of WR DLBCLs, together with
distinctive pathologic features, reinforce the concept that the
anatomic location is a major determinant of DLBCL
heterogeneity, and might suggest that WR DLBCLs could
constitute a biologically distinct DLBCL subgroup.
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International models of investigator-initiated
trials: implications for Japan
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Background: Academic/institutional investigator-initiated clinical trials beneﬁt individuals and society by supplementing
gaps in industry-sponsored clinical trials.
Materials: In May 2010, experts from Japan, the Republic of Korea, the UK, and the United States, met at a
symposium in Tokyo, Japan, to discuss how policies related to the conduct of clinical trials, which have been shown to
be effective, may be applied to other regions of the world.
Results: In order to increase the availability of anticancer drugs world-wide, nations including Japan should examine
the beneﬁts of increasing the number of investigator-initiated clinical trials. These trials represent one of the most
effective ways to translate basic scientiﬁc knowledge into clinical practice. These trials should be conducted under GCP
guidelines and include Investigational New Drug application submissions with the ultimate goal of future drug approval.
Conclusions: To maximize the effectiveness of these trials, a policy to educate health care professionals, cancer
patients and their families, and the public in general on the beneﬁts of clinical trials should be strengthened. Finally,
policies that expedite the clinical development of novel cancer drugs which have already been shown to be effective in
other countries are needed in many nations including Japan to accelerate drug approval.
Key words: academic/institutional investigator-initiated clinical trials, anticancer drugs, good clinical practice, health
care policy, international clinical trials, patient advocates
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